ERBB2 and breast carcinoma: Lapatinib is a small molecule that inhibits epidermal growth factor receptor/HER2 signalling in cancer cells, and its treatment efficacy has been well explored in breast cancer.2,4,6 However, the efficacy of continuing lapatinib after the failure of both trastuzumab and lapatinib has not been evaluated.